Allarity Therapeutics, Inc.
ALLR

NASDAQ > Biotechnology
DCF:$0.57  |   P/E: -
$0.05(2.92%)
Change
Rating:
Price: $1.71 USD
Market Cap: $2.49M

...Loading ALLR Peers...





Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

    5 Employees

    CEO : Mr. Thomas H. Jensen

    Address : 210 Broadway, Cambridge,MA, US, - 02139,

Key ExcutivesDesignation
Mr. Alexander EpshinskyChief Financial Officer
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D.Co-Founder
Dr. Steen Meier Knudsen Ph.D.Founder & Chief Scientific Officer
Mr. Thomas H. JensenFounder, Chief Executive Officer & Director